DEPO (Database of Evidence for Precision Oncology)

Overview

DEPO (Database of Evidence for Precision Oncology) is a curated resource that maps genomic alterations (mutations, fusions, copy-number changes) to targeted therapies with supporting clinical evidence. It allows off-label drug-alteration associations and is used to assess whether a given genomic event in a tumor is potentially “druggable” — i.e., targetable by an approved or investigational agent. In the TCGA fusion analysis, DEPO was the druggability annotation oracle.

Used by

• Used to annotate druggability of gene fusions across 9,624 TCGA tumor samples; identified 574 samples (6.0%) across 29 cancer types as harboring at least one druggable fusion (off-label inclusion permitted); major recurrent druggable targets included TMPRSS2 in PRAD, RET in THCA, PML-RARA in LAML, and FGFR3 across 15 cancer types PMID:29617662

Notes

• Off-label inclusion may overstate true clinical actionability; DEPO annotations do not account for co-occurring resistance alterations.
• The 6.0% druggable-fusion rate in the TCGA pan-cancer cohort should be interpreted as an upper bound of potential actionability, not confirmed therapeutic utility.
• DEPO is a curated database; updates to its content will change druggability classifications for the same events.

Sources

This page was processed by crosslinker on 2026-05-15.